Stockscreener 앱 받기
40.57
1.60%
-0.66
시간 외 거래:
40.57
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - ca.finance.yahoo.com
Supernus Announces Second Quarter 2025 Financial Results - ADVFN Brasil
RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it
CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks
Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
SUPN Stock Surge: What’s Driving It? - StocksToTrade
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - Yahoo Finance
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada
Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Canada
Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest
Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox
Supernus: Q2 Earnings Snapshot - New Haven Register
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance
Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Supernus Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Supernus Pharmaceuticals Delivers Growth With Qelbree And GOCOVRI - Finimize
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals Q2 2025: Navigating Contradictions in ONAPGO, Qelbree, and ZURZUVAE Growth - AInvest
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - Yahoo Finance
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses By Investing.com - Investing.com South Africa
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses - Investing.com
Supernus Pharmaceuticals Q2 revenue falls - MarketScreener
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Report PreviewNews and Statistics - IndexBox
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
When is Supernus Pharmaceuticals Inc. stock expected to show significant growthExceptional growth trajectory - Jammu Links News
What makes Supernus Pharmaceuticals Inc. stock price move sharplyAchieve superior returns through strategic trading - Jammu Links News
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockFree Investment Timing Strategies - Jammu Links News
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Rapid market gains - Jammu Links News
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
Should I hold or sell Supernus Pharmaceuticals Inc. stock in 2025Build wealth steadily with proven methods - Jammu Links News
What are analysts’ price targets for Supernus Pharmaceuticals Inc. in the next 12 monthsStay ahead with daily expert stock picks - Jammu Links News
Is Supernus Pharmaceuticals Inc. a good long term investmentSuperior portfolio returns - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
SAGE Therapeutics Announces Nasdaq Delisting Following Merger and Board Changes - AInvest
What institutional investors are buying Supernus Pharmaceuticals Inc. stockTop Growth Ideas For 2025 - Jammu Links News
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com Nigeria
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
0.64%
2.58%
자본화:
|
볼륨(24시간):